Atuzaginstat is under clinical development by Lighthouse Pharmaceuticals and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Atuzaginstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COR-388 is under development for the treatment of Parkinson’s disease and periodontal disease. It is also used for the treatment of high-risk oral potentially malignant disorders (OPMDs), including oral/head and neck squamous cell cancer (O/HNSCC), high-risk oral pre-malignant dysplasia (PmD), proliferative verrucous leukoplakia (PVL), and carcinoma-in-situ (CIS). It is an orally-administered, brain-penetrating small molecule gingipain protease inhibitor.
It was also under development for mild to moderate Alzheimer's disease.
Lighthouse Pharmaceuticals overview
Lighthouse Pharmaceuticals (Lighthouse) is a biopharmaceutical company developing precision medicine candidates based on expertise in small molecule protease inhibition for the treatment of chronic degenerative and inflammatory disorders including dementia. Lighthouse is headquartered in Savannah, Georgia, the US.
For a complete picture of Atuzaginstat’s drug-specific PTSR and LoA scores, buy the report here.